Latest Breaking News On - Shiran zimri - Page 4 : comparemela.com

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomLoma linda universityUnited statesSan franciscoNiva russekJeremy shefnerJeffrey rosenfeldCharles duncanFerenc tracikShiran zimriNedira salzman frenkelAmyotrophic lateral sclerosis consortiumNeurosense head of the scientific programCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administration

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesSan diegoUnited kingdomClearwater beachNiva russek blumShiran zimriFerenc tracikAmyotrophic lateral sclerosis consortiumNeurosense head of scientific programResearch ambassadorsInternational symposiumPrnewswire neurosense therapeutics ltdNeurosense therapeutics ltdHot topicSociety for neuroscience sfnNeals peace committee

NeuroSense Therapeutics to Present at Upcoming U S and European ALS Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomUnited statesFernando vieiraSeanm healeyRobert brownSabrina paganoniJames berryFerenc tracikShiran zimriTherapy development institutePrnewswire neurosense therapeutics ltdDrug administrationHead of scientific program at neurosenseNeurosense therapeutics ltdResearch symposiumEuropean medicines agency

Neurosense Therapeutics (NRSN) Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Neurosense Therapeutics (NRSN) Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Erez eitanAvital pushettVivian droryJeremym shefnerShiran zimriNeurosense head of scientific programBarrow neurological instituteClinical researchNeurosense therapeutics ltdSense therapeuticsAmyotrophic lateral sclerosisFrontotemporal degenerationScientific programNeuromuscular diseases unitTel aviv sourasky medical centerPrincipal investigator

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesErez eitanVivian droryJeremym shefnerShiran zimriNeurosense head of scientific programBarrow neurological instituteDrug administrationNeurosense therapeutics ltdClinical researchEuropean medicines agencyNeuromuscular diseases unitTel aviv sourasky medical centerPrincipal investigatorChief medical officerChief scientific officer